GlassScriptPhysician profile
Thomas T Jefferson
NPI 1790891448
$12,768.17
in general payments reported to CMS, 2019-2025
19 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,306 · 2020: $269 · 2021: $389 · 2022: $4,726 · 2023: $502 · 2024: $360 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10,820.88 | 2019-2025 | |
| Viiv Healthcare Company | $860.76 | 2019-2024 | Dovato, Cabenuva |
| Indivior INC. | $238.02 | 2019-2024 | Sublocade |
| Theratechnologies INC. | $217.02 | 2019-2025 | Egrifta, Trogarzo |
| Abbvie INC. | $94.26 | 2019-2023 | |
| Janssen Biotech, INC. | $93.78 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $66.27 | 2019-2025 | |
| Braeburn INC. | $59.69 | 2024 | Brixadi |
| Alkermes, INC. | $55.26 | 2023-2024 | Lybalvi, Vivitrol |
| Orexo US, INC. | $46.27 | 2019 | |
| Antares Pharma, INC. | $42.82 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Merck Sharp & Dohme LLC | $42.25 | 2019 | |
| Supernus Pharmaceuticals, INC. | $31.10 | 2023 | Qelbree |
| Redhill Biopharma INC. | $25.86 | 2023 | |
| Hologic Sales and Service, LLC | $17.24 | 2025 | Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.13 | 2023 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $14.99 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.38 | 2024 | Uzedy |
| Myovant Sciences INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jefferson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.